受体酪氨酸激酶MET作为多激酶抑制剂及放射增敏剂索拉非尼在头颈部鳞状细胞癌中的潜在靶点
该研究通过抗体芯片、蛋白质印迹、增殖和生存实验分析索拉非尼及MET抑制剂克唑替尼和SU11274在头颈部鳞状细胞癌(HNSCC)细胞中的作用,发现索拉非尼抑制表皮生长因子受体和MET的自身磷酸化,但索拉非尼的细胞毒性和放射增敏作用与MET水平无关,MET抑制剂仅轻度细胞毒性且无放射增敏作用,提示MET是索拉非尼的新潜在靶点但非其细胞毒性或放射增敏的原因。
要点
- 索拉非尼抑制HNSCC细胞中表皮生长因子受体和MET的自身磷酸化
- 索拉非尼的细胞毒性和放射增敏作用与MET表达水平无关
- MET抑制剂克唑替尼和SU11274仅引起轻度细胞毒性且无放射增敏作用
核心结论
- 研究确定MET是索拉非尼的新潜在靶点,但MET抑制并非索拉非尼介导的细胞毒性或放射增敏的原因。
研究设计与样本
- 研究使用基于玻片的抗体芯片、蛋白质印迹、增殖和生存实验分析索拉非尼及MET抑制剂克唑替尼和SU11274在头颈部鳞状细胞癌(HNSCC)细胞中的效果,并使用X射线进行照射。
主要发现
- 索拉非尼抑制表皮生长因子受体和MET的自身磷酸化,此前未见报道。
- HNSCC细胞中MET表达不总是与活性/磷酸化相关。
- 索拉非尼依赖的细胞杀伤和放射增敏与MET水平无关。
- MET抑制剂阻断增殖,但仅引起轻度细胞毒性且无放射增敏作用。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The multi-kinase inhibitor sorafenib displays antitumoral effects in head and neck squamous cell carcinoma (HNSCC); however, the targeted kinases are unknown. Here we aimed to identify those kinases to determine the mechanism of sorafenib-mediated effects and establish candidate biomarkers for patient stratification. METHODS: The effects of sorafenib and MET inhibitors crizotinib and SU11274 were analyzed using a slide-based antibody array, Western blotting, proliferation, and survival assays. X-rays were used for irradiations. RESULTS: Sorafenib inhibited auto-phosphorylation of epidermal growth factor receptor and MET, which has not been described previously. MET expression in HNSCC cells was not always associated with activity/phosphorylation. Furthermore, sorafenib-dependent cell kill and radiosensitization was not associated with MET level. Although MET inhibitors blocked proliferation, they caused only mild cytotoxicity and no radiosensitization. CONCLUSION: We identified MET as a new potential target of sorafenib. However, MET inhibition is not the cause for sorafenib-mediated cytotoxicity or radiosensitization.
引用
- Beizaei K, Gleißner L, Hoffer K, et al. Receptor tyrosine kinase MET as potential target of multi-kinase inhibitor and radiosensitizer sorafenib in HNSCC. Head Neck. 2018. PMID: 30552828. doi:10.1002/hed.25440
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。